IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, scientists at the Centers for Disease Control and Prevention (CDC) announced that they were…
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
On May 12, 2022, WHOメs COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Centers for Disease Control and Prevention (CDC) reported that a person had tested positive…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 20, 2022, Codiak BioSciences announced new preclinical data from its pan beta-coronavirus vaccine program, which aims…
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…
On Apr. 15, 2022, The Idaho State Department of Agriculture (ISDA) announed it had received confirmation of multiple…
On Apr. 14, 2022, Merck announced that V116, the companyメs investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
On Apr. 8, 2022, Novavax announced and Serum Institute of India (SII), the world’s largest vaccine manufacturer by…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Apr. 3, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
On Mar. 31, 2022, Novavax announced submission of its request to expand the conditional marketing authorization (CMA) of…